hit counter
Blueprint Medicines Corporation (BPMC) Stock News Sentiment & Price - Sentifly
BPMC - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Blueprint Medicines Corporation (BPMC)

USA
Biotechnology
NASDAQ
BPMC Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BPMC Latest news
PRNewsWire
Neutral
Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
2021-11-09 08:00

CAMBRIDGE, Mass. and SHANGHAI and SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

PRNewsWire
Neutral
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-11-05 16:01

CAMBRIDGE, Mass., Nov. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on November 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 24,373 shares of its common stock and an aggregate of  12,183 restricted stock units (RSUs) to eighteen new employees under Blueprint Medicines' 2020 Inducement Plan.

Zacks Investment Research
Neutral
Blueprint Medicines (BPMC) Misses on Q3 Earnings & Revenues
2021-10-29 12:59

Blueprint Medicines (BPMC) misses earnings and revenue estimates for the third quarter of 2021. Yet, the stock price surges as the company provides encouraging pipeline updates.

Seeking Alpha
Neutral
Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q3 2021 Results - Earnings Call Transcript
2021-10-28 15:14

Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates
2021-10-28 09:56

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -18.34% and -39.72%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire
Neutral
Blueprint Medicines Reports Third Quarter 2021 Financial Results
2021-10-28 07:00

CAMBRIDGE, Mass., Oct. 28, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the third quarter ended September 30, 2021.

PRNewsWire
Neutral
Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
2021-10-21 08:00

CAMBRIDGE, Mass., Oct. 21, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.

PRNewsWire
Neutral
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-10-05 16:01

CAMBRIDGE, Mass., Oct. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on October 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 24,068 shares of its common stock and an aggregate of 12,033  restricted stock units (RSUs) to eight new employees under Blueprint Medicines' 2020 Inducement Plan.

PRNewsWire
Neutral
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-09-03 16:01

CAMBRIDGE, Mass., Sept. 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on September 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 23,720 shares of its common stock and an aggregate of 11,858 restricted stock units (RSUs) to 12 new employees under Blueprint Medicines' 2020 Inducement Plan.

PRNewsWire
Neutral
Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-02 08:00

CAMBRIDGE, Mass. , Sept. 2, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D.

Loading more news...